Q2057 Afamitresgene autoleucel
Also known as: Imlygic, afamitresgene autoleucel, TCR therapy
Afamitresgene autoleucel autologous T-cell immunotherapy targeting PRAME for melanoma and other PRAME-expressing malignancies.
In Plain Language
cancer cell fighter; engineered cell therapy
Clinical Context
Autologous T-cell therapy targeting PRAME (Preferentially Expressed Antigen in Melanoma). Used for melanoma and other PRAME+ cancers.
RVU Information
CPT Q2057 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2057?
CPT Q2057 (Afamitresgene autoleucel) is a Q Codes code. Afamitresgene autoleucel autologous T-cell immunotherapy targeting PRAME for melanoma and other PRAME-expressing malignancies.
Is Q2057 covered by insurance?
Q2057 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Autologous T-cell therapy targeting PRAME (Preferentially Expressed Antigen in Melanoma). Used for melanoma and other PRAME+ cancers.
When is CPT Q2057 used?
Autologous T-cell therapy targeting PRAME (Preferentially Expressed Antigen in Melanoma). Used for melanoma and other PRAME+ cancers.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.